Loading clinical trials...
Loading clinical trials...
BRCA1/2 mutation carriers have a considerably increased risk to develop breast and ovarian cancer during their lifetime. There is evidence from the literature that for sporadic breast cancer disease r...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Technical University of Munich
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT05130606 · Hereditary Breast and Ovarian Cancer
NCT03124212 · Hereditary Breast and Ovarian Cancer, Lynch Syndrome
NCT02516540 · Hereditary Breast and Ovarian Cancer
NCT05677048 · Gynecologic Cancer, Ovary Cancer, and more
University of Cologne
Cologne
University of Schleswig-Holstein Campus Kiel
Kiel
Technische Universitaet Muenchen
Munich
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions